Updates

WhiteNest Pharma is excited to announce a pivotal partnership with a leading Contract Development and Manufacturing Organisation (CDMO) that specializes in pharmaceutical Good Manufacturing Practices (GMP) conditions and holds the Manufacturing Importation Authorisation (MIA) for our product category. This strategic… Read More »WHITENEST PHARMA ANNOUNCES STRATEGIC CDMO PARTNERSHIP TO ACCELERATE LYSADERM DEVELOPMENT

WhiteNest Pharma announces an upcoming MDR inspection by KIWA Cermet for the BioNest 12D, BioNest 2.0, and BioNest Transfer systems on March 13-14. This pivotal review is expected to secure a new certification for these innovative systems, reinforcing our commitment… Read More »WHITENEST PHARMA ANTICIPATES MDR CERTIFICATION FOR BIONEST SYSTEMS

WhiteNest Pharma is excited to announce the completion of the planning phase for an innovative pharmaceutical plant dedicated to manufacturing lyophilized cord blood and adult blood platelets. This significant milestone paves the way for the production of high-value pharmaceutical applications,… Read More »WHITENEST PHARMA COMPLETES PROJECT PLANNING FOR INNOVATIVE PHARMACEUTICAL PLANT

WhiteNest Pharma is proud to announce a strategic collaboration with a prestigious university’s Pharmacological Sciences Department to enhance the formulation of Lysaderm, aiming at scalability for global markets while upholding the highest quality standards. This partnership signifies our dedication to… Read More »WHITENEST PHARMA INITIATES COLLABORATIVE RESEARCH TO ADVANCE LYSADERM’S FORMULATION

A recent study published in Blood Transfusion (2023; doi: 10.2450/BloodTransfus.492) details the successful validation of WhiteNest Pharma’s BioNest 2.0 system in a multi-component cord blood banking exercise. This international study, involving 12 public cord blood banks from Spain, Italy, Greece,… Read More »WHITENEST PHARMA’S BIONEST 2.0 SYSTEM VALIDATES MULTI-COMPONENT CORD BLOOD BANKING, REPORTED IN BLOOD TRANSFUSION JOURNAL

WhiteNest Pharma announces a pivotal moment in the quest for innovative periodontal treatments. Our latest project, focused on the use of lyophilized umbilical cord blood platelet lysate for periodontal regeneration, has been meticulously developed and is now poised for the… Read More »ADVANCEMENT IN PERIODONTAL REGENERATION STUDY AWAITS FINAL APPROVAL

WhiteNest Pharma announces a pivotal advancement for non-transfusional blood components in Italy, following the Centro Nazionale Sangue’s (CNS) recent clarification on national tariffs, as detailed in their FAQ section. This update directly impacts the use of adult blood allogenic platelets… Read More »NEW CNS CLARIFICATION ENHANCES ACCESS TO BIONEST 12D IN ITALY

WhiteNest Pharma has achieved a significant milestone by entering into an agreement that promises to significantly propel its pharmaceutical project forward. This strategic move underscores our commitment to innovation in the development of lyophilized cord blood and adult blood platelets,… Read More »WHITENEST PHARMA SECURES NEW AGREEMENT FOR PHARMACEUTICAL PROJECT ADVANCEMENT